|Posted by JJ The Psychotherapist on August 19, 2021 at 10:40 AM|
Landmark Study Proves COVID Vaccines Much Less Effective Than Advertised
The University of Oxford and the UK Office for National Statistics have just published the largest study to date on the efficacy of COVID vaccines in the wild, and unsurprisingly, it found that efficacy rates for Pfizer and Moderna are significantly lower than the 90%+ rates first advertised from the initial controlled trials.
While the Pfizer, Moderna, and AstraZeneca vaccines still provide "excellent" protection against new infections, their efficacy has been lowered when compared to Alpha, according to the study, which was published as a preprint on Thursday. While two doses of either vaccination provide "at least the same amount of protection as having had COVID-19," those who were vaccinated after being infected showed even better protection than those who were either not sick and just had the jabs, or were infected but did not receive the jabs.
"We’re seeing here the real-world data of how two vaccines are performing, rather than clinical trial data, and the data sets all show how the delta variant has blunted the effectiveness of both the Pfizer and AstraZeneca jabs," said Simon Clarke, an associate professor in cellular microbiology at the University of Reading.
Despite this, those infected with delta had considerably greater peak levels of the virus than those infected with alpha or another variety, even after getting two doses of the vaccine.
The study also revealed disparities amongst vaccines: the Moderna vaccine, for example, had "similar or greater effectiveness" against the delta version than a single dose of the others. While the Pfizer and Moderna vaccines were initially more effective against infection than the AstraZeneca vaccine, this advantage fades after only 4-5 months.
Delta boosts transmissibility more than other COVID variants, even among the vaccinated, according to the research, which supports a recent evaluation by the American CDC.
According to Sarah Walker, an Oxford professor of medical statistics and epidemiology who helped lead the study, the findings cast greater doubt on the likelihood of obtaining herd immunity through vaccination. That comes as no surprise.
Finally, according to Penny Ward, a visiting professor in pharmaceutical medicine at King's College London who wasn't involved with the study but spoke to Bloomberg about its findings, data relating to hospitalizations and severe cases of COVID is still absent. According to her, the findings could promote "cross-vaccination" with various types of vaccines, which could provide more comprehensive protection.